Skip to main content
Premium Trial:

Request an Annual Quote

SignalGene to Acquire GeneScape Along with $3.7 M Private Placement

Premium

M

ONTREAL--SignalGene here has agreed to acquire GeneScape, a company with drug target identification and validation technologies, in a stock transaction valued at $12.7 million. The agreement includes a private placement totaling $2.7 million by two of GeneScape’s current shareholders, the Business Development Bank of Canada and Royal Bank Venture. An additional $1 million will be invested directly into SignalGene by Societe Innovatech du Grand Montreal when the acquisition closes, expected by March 20.

Filed under

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.